Iressa治疗中晚期非小细胞肺癌30例的分析  

Evaluation of IRESSA treatment in 30 patients with advanced non-small cell lung cancer

作　　者：孔进[1] 陈良安[1] 田庆[1] 范保星[1] 梁志欣[1] 王平[1] 于国[2] 

机构地区：[1]解放军总医院呼吸科,北京100853 [2]解放军总医院病理科,北京100853

出　　处：《军医进修学院学报》2006年第6期409-411,共3页Academic Journal of Pla Postgraduate Medical School

摘　　要：目的：观察Iressa治疗晚期非小细胞肺癌（NSCLC）的近期疗效和毒副作用。方法：30例经病理或细胞学证实的Ⅲ～Ⅳ期NSCLC患者口服Iressa 250mg 1／d，直至死亡或出现严重不良反应或病灶进展。每月一次肺部CT扫描，以评价其疗效，同时记录不良反应。结果：30例患者中完全缓解（CR）0例，8例达部分缓解（PR），15例稳定（SD），7例病情进展（PD），部分缓解率26．7％，有效率（RR）26．7％，疾病控制率（CR＋PR＋SD）76．7％。其中全组患者中位肿瘤进展时间4个月，中位生存时间6．5个月，女性疗效优于男性。主要毒副作用为皮疹和腹泻。结论：口服Iressa对于放化疗失败或不能耐受放化疗的晚期NSCLC患者有效且安全、耐受性良好。Objective：To observe the effect of Iressa on patients with advanced non-small cell lung cancer （NSCLC）. Methods ： Thirty patients with stage Ⅲ-Ⅳ NSCLC pathologically or cytologically proved were enrolled in this study. Orally Iressa 250mg daily were given to patients with advanced NSCLC until severe toxicity or disease progress occurred, CT scan was performed for response assessment by month. Results：Among the 30 patients, 0 complete response （CR）and 8 partial response （PR）were observed, 15 stable disease, 7 progress disease. The overall response rate was 26.7% and disease control rate including both tumor response and stable disease was 76.7%. Median time to progress of entire group was 4 months. Median survival time was 6.5 months. Female had higher response rate than male. The main toxicity of Iressa was skin toxicity （rash） and diarrhea. Condusion： Monotherapy using Iressa is effective and tolerable for the patients with advanced NSCLC who were intolerable or failed prior radiotherapy and chemotherapy.

关 键 词：癌 非小细胞肺 IRESSA 受体 表皮生长因子 

分 类 号：R734.2[医药卫生—肿瘤]